STAT3 and non-small cell lung carcinoma: Overall, these findings indicated that PROS acts as an effective anticancer agent for NSCLC via its ability to exhibit both antiangiogenic and apoptotic effects mediated via the inhibition of STAT3/VEGF/CDK2 signaling pathway[50].